The US FDA has approved CSL's HEMGENIX (etranacogene dezaparvovec-drlb) as the first and only one-time gene therapy for appropriate adults with haemophilia B.
CSL secures US approval for breakthrough one-time haemophilia gene therapy
November 24, 2022 Latest NewsBioPharma
Latest Video
New Stories
-
Bristol Myers Squibb Australia riders more than double their target for Rare Cancers Australia
November 10, 2026 - - Latest News -
Dispatch AI Index finds routine AI use but questions over governance
November 10, 2026 - - News of the Day -
Mayne Pharma sells Salisbury business to Evaris Pharma for $55.5 million
November 10, 2026 - - Latest News -
Pfizer commissioned polling finds strong public support for investing in the PBS
November 9, 2026 - - Latest News -
Pfizer confirms Ben Fitzsimmons as Australia and New Zealand chief
November 9, 2026 - - Latest News -
Coalition edges ahead in New Zealand as Stephenson returns and Pharmac pledges await the 'specials'
November 9, 2026 - - Latest News -
Celairis launches with plan to end the region's place at the rear of the launch queue
November 9, 2026 -

